Mitigating murine acute and chronic Coxsackievirus B3-induced myocarditis with human right atrial appendage-derived stromal cells
Stem Cells Translational Medicine · 2025
DOI: 10.1093/stcltm/szae103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2025. Verfasst von Muhammad El-Shafeey und 12 weiteren Autor:innen. Beteiligte Einrichtung: Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany. Hauptthemen laut MEDLINE: Myocarditis, Coxsackievirus Infections, Enterovirus B, Human, Atrial Appendage. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Berlin-Brandenburg Center for Regenerative Therapies.
Abstract (Originalsprache)
We previously have shown the potential of human endomyocardial biopsy (EMB)-derived cardiac adherent proliferating cells (CardAPs) as a new cell-therapeutic treatment option for virus-induced myocarditis. To overcome the limited cell yield per EMB, CardAPs have been isolated from the human right atrial appendage (RAA) in view of allogeneic application and off-the-shelf use. We aimed to investigate the cardioprotective and immunomodulatory potential of RAA-CardAPs in experimental acute and chronic Coxsackievirus B3 (CVB3)-induced myocarditis upon injection in the viral and inflammatory phase. In the acute model, male C57BL6/J mice were intraperitoneally (i.p.) injected with the CVB3 Nancy strain or phosphate buffered saline (PBS). One day after infection, mice were intravenously (i.v.) injected with RAA-CardAPs, EMB-CardAPs (as reference cells) or PBS. For the chronic model, male Naval Medical Research Institute mice were i.p. injected with the CVB3 31-1-93 strain or PBS. Ten days after infection, mice were i.v. injected with RAA-CardAPs. Cardiac function was characterized, followed by harvest of the left ventricle (LV) and spleen for subsequent analysis, 7 and 28 days after CVB3 infection in the acute and chronic model, respectively. In the acute model, RAA-CardAPs decreased cardiac fibrosis and improved cardiac function in CVB3 mice. RAA-CardAPs mice exerted immunomodulatory effects as evidenced by lower LV chemokines expression (C-C motif ligand [CCL]2 and CCL7), CD68+ cells presence, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, tumor necrosis factor-α, and IL-6 mRNA expression. In the chronic model, RAA-CardAPs reduced cardiac fibrosis and the severity of myocarditis, associated with an improvement in LV function. We conclude that RAA-CardAPs represent a treatment strategy to reduce the development of acute and chronic CVB3-induced myocarditis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany.
- DZHK (German Center for Cardiovascular Research) Partner Site, Berlin, Germany.
- Medical Biotechnology Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications, 21934 Alexandria, Egypt.
- Division of Cardiology, Foundation for Medical Research, Department of Medicine, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.
- Deutsches Herzzentrum der Charité (DHZC), Department of Cardiology, Angiology and Intensive Medicine, Campus Virchow Klinikum, 13353 Berlin, Germany.
- Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, 13353 Berlin, Germany.
ORCID-Profile: Muhammad El-Shafeey, Kapka Miteva, Henry Fechner, Jens Kurreck, Karin Klingel, Carsten Tschöpe, Sophie Van Linthout
Förderung
- Berlin-Brandenburg Center for Regenerative Therapies
Zitieren
APA
El-Shafeey, M., Pappritz, K., Voss, I., Miteva, K., Alogna, A., Seifert, M., Fechner, H., Kurreck, J., Klingel, K., Haag, M., Sittinger, M., Tschöpe, C., & Van Linthout, S. (2025). Mitigating murine acute and chronic Coxsackievirus B3-induced myocarditis with human right atrial appendage-derived stromal cells. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szae103
Vancouver
El-Shafeey M, Pappritz K, Voss I, Miteva K, Alogna A, Seifert M, et al. Mitigating murine acute and chronic Coxsackievirus B3-induced myocarditis with human right atrial appendage-derived stromal cells. Stem Cells Translational Medicine. 2025. doi:10.1093/stcltm/szae103
BibTeX
@article{ElShafeey2025,
author = {El-Shafeey, Muhammad and Pappritz, Kathleen and Voss, Isabel and Miteva, Kapka and Alogna, Alessio and Seifert, Martina and Fechner, Henry and Kurreck, Jens and Klingel, Karin and Haag, Marion and Sittinger, Michael and Tschöpe, Carsten and Van Linthout, Sophie},
title = {Mitigating murine acute and chronic Coxsackievirus B3-induced myocarditis with human right atrial appendage-derived stromal cells},
journal = {Stem Cells Translational Medicine},
year = {2025},
doi = {10.1093/stcltm/szae103}
}
EUVIMED